Dharan Cancer Speciality Centre, Salem’s Post

A breakthrough in cancer therapy is upon us! 🎉 The FDA has approved Bristol Myers Squibb's Breyanzi for mantle cell lymphoma - now a beacon of hope for patients with limited options. This advanced CAR-T cell therapy has shown high response rates and holds a consistent safety profile, providing a potentially life-altering one-time infusion treatment 🦠 With MCL prognosis typically dimming at every relapse, Breyanzi emerges as a crucial option, potentially turning the tables on this aggressive form of lymphoma. The approval, hinging on impressive trial results, solidifies Breyanzi as a front-runner in the realm of CAR-T therapies for B-cell malignancies 🔎🩺 For the warriors battling relapsed or refractory MCL, this is a momentous stride towards more personalized, effective treatments. Here's to groundbreaking medical innovations that continue to light the way! ✅ #BristolMyersSquibb #BMS #CancerTherapy #Innovation #Breyanzi #Oncology #ClinicalTrials #ClinicalResearch #LifeScience #StaffingPartner #ElixirAssociates

September is #Lymphoma Awareness Month. Clinical implementation of novel immunotherapy regimens for Hodgkin and non-Hodgkin lymphoma has expanded treatment options and improved outcomes for many patients, especially advanced stage disease. Pairing immunotherapy agents (mAbs, ADCs, ICIs, cellular therapies) with other treatments, such as chemotherapy, has armed these patients with highly effective strategies to fight back against lymphoma! Visit the SITC Lymphoma CPG as published in the Journal for ImmunoTherapy of Cancer or via SITC’s CPG Mobile App to view the current recommendations for the treatment of lymphoma using immunotherapy approaches. The app features interactive decision-support tools as well as notifications for rapid updates based on new regulatory approvals or practice-changing data. https://ow.ly/YaPV50To8HP #Lymphoma #lymsm #BloodCancer #HodgkinsLymphoma #NonHodgkinsLymphoma

Join us this August for two exciting free webcasts led by healthcare experts! 🗓️ Wednesday, August 7th @ 3 – 4 pm ET 🔬 Microscope on MDS (Myelodysplastic syndromes) Dr. Heather Leitch, a hematologist and specialist in myelodysplastic syndromes (MDS), will give updates on this group of cancers of the blood and bone marrow. Learn about the medical and scientific work underway to improve outcomes and save more lives of people living with MDS. 🗓️ Wednesday, August 14th @ 4 – 5 pm ET ⚛️ Deep dive into DLBCL (diffuse large B-cell lymphoma) Join Dr. John Kuruvilla, a hematologist and expert in high-precision treatments in oncology, for this 1-hour live online presentation about managing diffuse large B-cell lymphoma, DLBCL, which is the most commonly diagnosed subtype of non-Hodgkin lymphoma. To learn more and to register, visit https://bit.ly/3t6Loqe #MDS #DLBCL #diffuselargebcelllymphoma #lymphoma #myelodysplasticsyndromes #bloodcancers #hemaoncology #nonhodgkinlymphoma #bloodcancer

💡 NEW FINDINGS: A recent CCR advance featured in Cancer Cell (Cell Press) identified several tumor-specific features and microenvironmental patterns in follicular lymphoma patients who experience early relapse. Understanding these factors may inform the selection of novel therapeutic approaches for these patients. National Cancer Institute (NCI), National Institutes of Health (NIH): Intramural Research Program (IRP) Follicular lymphomas comprise about 35% of adult non-Hodgkin lymphomas in the U.S. and 22% worldwide. Most patients have widespread disease at diagnosis. Morphologically, follicular lymphomas are classified as Grade 1, Grade 2, and Grade 3, depending on the percentage of the large lymphocytes present. ➡ Read the full article here: https://lnkd.in/e_Bcidjw #CancerResearch #Lymphoma #Health #Innovation #Medicine

🚀 Exciting Advances in DLBCL Treatment! 🚀 Healthcare professionals, explore the cutting-edge of oncology with BiTEs and CAR-T therapies for Diffuse Large B-cell Lymphoma (DLBCL). BiTEs engage the immune system by linking T-cells to cancer cells, offering a novel approach for relapsed/refractory cases. Meanwhile, CAR-T therapy personalizes the fight against cancer by engineering patient T-cells to target and destroy lymphoma cells. 🔍 Key Considerations: - Disease characteristics & patient-specific factors - Treatment availability & logistics - Efficacy and safety profiles Stay tuned for more updates as we navigate the future of hematological malignancy treatments together! #DLBCL #BiTEs #CARTtherapy #OncologyInnovation

Today we announced that Dr. Shouse, the Principal Investigators at City of Hope, was invited to present his experience from our clinical study in patients with #lymphoma (APOLLO study) at the 11th Global Summit on Hematologic Malignancies.   Marker’s Phase 1 #APOLLO study is investigating MT-601, a #multiTAA-specific T cell product, for the treatment of patients with #lymphoma who have #relapsed or are #ineligible to receive #CAR T cell therapy.   Key Highlights: 🌟 Three patients were treated at City of Hope as part of the #APOLLO study. 🌟 First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed 4 prior lines of therapy, including a relapse within 90 days of CAR T cell therapy. This participant achieved a #CompleteResponse 8 weeks after the second infusion of MT-601 and remains in complete response #9 #months after initial treatment with MT-601. 🌟 Another study participant was diagnosed with follicular lymphoma that transformed into DLBCL. This participant failed 12 lines of therapy, including CAR T cells. 8 weeks after treatment with MT-601, the study participant achieved a #CompleteResponse, which is maintained 3 months following initial treatment with MT-601. 🌟 The third study participant treated at City of Hope had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a #PartialResponse 8 weeks after MT-601 treatment with all lesions decreasing in size including one that has completely resolved.   🌟 Treatment was well tolerated among all patients with no significant treatment-related adverse events.     For more information: https://lnkd.in/gVgUburj    #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

🙌 🙌 Delighted to provide this commentary for The Lancet journal about the recently published German Hodgkin Study Group (GHSG) report "Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial" (see full publication HERE: https://lnkd.in/eF7tAFW9). 👏 👏 A hearty congratulations to the GHSG for the results from the HD21 study that show the superiority of the innovative treatment platform of #PET-guided (i.e., response-adapted) #BrECADD for adults with classical Hodgkin #lymphoma (with an unprecedented 4-year PFS of 94%) as well as for 50+ years of successive generations of pivotal clinical studies conducted by the GHSG (see HERE: https://lnkd.in/ePc8XNBH). ➡ ➡ Therapy for cHL has undergone a remarkable #evolution over the past 60 years since the development of MOPP in 1964 with a 5-year OS of 50% (which is now >95%!!). Despite this success, there remain opportunities to improve outcomes (e.g., globally standardize definitions, further reduce the reliance on cytotoxic therapy, identify equally effective & tolerable regimens for #pediatric & #olderpatients, and establish more robust predictive tools & decision models that promote #personalized cancer care). Onward & upward! #cancerresearch #cancercare #HodgkinLymphoma #survivorship #clinicaltrials #clinicalresearch #decisionmaking #precisionmedicine #innovation Rutgers Health, Rutgers Cancer Institute, RWJBarnabas Health

Breast cancer 6 #Radiation_therapy Radiation therapy has a significant role in local disease control. Radiation therapy Is #not_necessarily for women 70 years of age and older with small, lymph node-negative, hormone receptor-positive (HR+) cancers. Radiation therapy is #beneficial in large tumors (greater to 5 cm) or if the tumor invades skin or chest wall and if there are positive lymph nodes. It can also be used as palliative therapy in advanced cases, such as a central nervous system (CNS) or bone metastasis. It can be delivered as external beam radiation, brachytherapy, or a combination of both. #breast_cancer #oncology #chemotherapy #drugs #pharmacy #pharmacist

🌍 World Blood Cancer Day 🩸 🔬 Enhancing Blood Cancer Diagnosis and Staging Blood cancers like lymphoma and leukemia often require precise imaging for accurate diagnosis and staging. Modern CT scans have proven essential, particularly when these cancers spread to the lymph nodes, liver, or spleen, aiding in early detection and intervention. 📊 Smart Reporting GmbH Reporting in Lymphoma Staging: Leveraging Advanced Imaging The Lugano classification, the leading staging system for lymphoma, depends significantly on CT and PET-CT scans. Smart reporting technology now enables radiologists to analyze and share imaging results more efficiently and accurately. This technology ensures detailed, standardized reports that enhance the staging process, making it more reliable and informative for oncologists and patients alike. 💡 #Benefits of Smart Reporting: 𝗖𝗼𝗻𝘀𝗶𝘀𝘁𝗲𝗻𝗰𝘆: Ensures standardized reporting across different healthcare providers. 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆: Speeds up the diagnostic process, allowing for quicker treatment decisions. 𝗔𝗰𝗰𝘂𝗿𝗮𝗰𝘆: Reduces the risk of human error, providing more precise staging information. 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻: Facilitates better communication between multidisciplinary teams, improving overall patient care. 🔗 Embracing smart reporting in oncology means better diagnostics, tailored treatments, and improved patient outcomes. It's a step forward in our quest for personalized and efficient cancer care. #SmartReporting #HealthcareInnovation #Oncology #Lymphoma #Leukemia #MedicalImaging #CTScan #PETCT #LuganoClassification #CancerDiagnosis #PersonalizedMedicine #PatientCare

Lymphoma is a type of cancer caused by the uncontrolled growth of cells called lymphocytes that play a role in fighting infection. Lymphoma is the most common cancer found in people 16 to 29 years old, with over 7,000 new cases diagnosed every year in Australia. More than 30 different types of this devastating disease have been identified. Treatment may involve chemotherapy, radiation therapy, the use of stem cell transplants or immunotherapy such as CAR T-cell therapy. 15th September is World Lymphoma Awareness Day. Let us make an impact on this Day by raising its awareness. At GreenLight Clinical (#GLC), we aim to strengthen our Lymphoma #community by supporting clinical trials for the development of drugs for treating lymphoma. To find out more about GLC, please visit www.greenlightclinical.com #WLAD2024 #greenlightclinical #businessdevelopment #biotech #medtech #clinicaltrials